Insider · CIK 0001685720
Kathryn C Zoon
Files at EBS (Emergent BioSolutions Inc.). First filing Mar 12, 2025, latest May 4, 2026.
In brief
Kathryn C Zoon files SEC Form 4 as director at EBS (Emergent BioSolutions Inc.). Since Mar 12, 2025, Kathryn C Zoon has reported 0 open-market buys worth $0 and 3 open-market sells worth $265k, the latest filed on May 4, 2026.
A track record needs three past buys with six months of prices behind them; Kathryn C Zoon has 0, so none is measured yet.
The newest scored trade: sold $144k of EBS on May 1, 2026, filed May 4, 2026, scored 26 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $144k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EBS: Emergent BioSolutions Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | Emergent BioSolutions Inc. | $144k 17,202 shares | -18% | +79% from low-39% from high | |
| 11Weak | Emergent BioSolutions Inc. | $63k 7,086 shares | -9% | +108% from low-26% from high | |
| 35Weak | Emergent BioSolutions Inc. | $57k 10,000 shares | -18% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 1, 2026 | EBS EMERGENT BIOSOLUTIONS INC. | 17,202 0.03% of outstanding | $144k | May 1, 2026 | none |
| Aug 15, 2025 | EBS EMERGENT BIOSOLUTIONS INC. | 7,086 0.01% of outstanding | $63k | Aug 15, 2025 | none |
| Mar 12, 2025 | EBS Emergent BioSolutions Inc. | 10,000 0.02% of outstanding | $57k | Mar 12, 2025 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | EBS Emergent BioSolutions Inc. | AGrant or award Common Stock10b5-1 | +25,344 | $0.00 | $0 | 97,143 | May 4, 2026 |
| May 1, 2026 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock10b5-1 | -16,145 | $8.36 | $135k | 80,998 | May 4, 2026 |
| May 1, 2026 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock10b5-1 | -1,057 | $8.97 | $9,481 | 79,941 | May 4, 2026 |
| Apr 30, 2026 | EBS Emergent BioSolutions Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +11,296 | $0.00 | $0 | 11,296 | May 4, 2026 |
| Aug 15, 2025 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock10b5-1 | -7,086 | $8.87 | $63k | 71,799 | Aug 18, 2025 |
| Apr 30, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Common Stock | +34,403 | $0.00 | $0 | 78,885 | May 2, 2025 |
| Apr 30, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Stock Option (Right to Buy)derivative | +15,824 | $0.00 | $0 | 41,572 | May 2, 2025 |
| Mar 12, 2025 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock | -10,000 | $5.73 | $57k | 44,482 | Mar 12, 2025 |
Questions about Kathryn C Zoon
Answered from the filings on this page, as of the latest one.
Is Kathryn C Zoon buying or selling?
In the last 12 months Kathryn C Zoon reported 0 open-market buys worth $0 and 1 open-market sell worth $144k on SEC Form 4; the latest was sold $144k of EBS on May 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Kathryn C Zoon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kathryn C Zoon has 0.
Where does Kathryn C Zoon file Form 4?
Kathryn C Zoon has filed Form 4 at EBS (Emergent BioSolutions Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.